A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs BMS 986165 (Primary)
  • Indications Autoimmune disorders; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Oct 2017 Planned number of patients changed from 12 to 20.
    • 25 Oct 2017 Planned End Date changed from 12 Oct 2017 to 13 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top